ChoA Pharmaceutical Co.Ltd (KQ:034940) — Market Cap & Net Worth
Market Cap & Net Worth: ChoA Pharmaceutical Co.Ltd (034940)
ChoA Pharmaceutical Co.Ltd (KQ:034940) has a market capitalization of $11.34 Million (₩16.73 Billion) as of September 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26831 globally and #2025 in its home market, demonstrating a -1.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChoA Pharmaceutical Co.Ltd's stock price ₩2700.00 by its total outstanding shares 6195965 (6.20 Million). Also see 034940 total assets for a full breakdown of the balance sheet.
ChoA Pharmaceutical Co.Ltd Market Cap History: 2015 to 2026
ChoA Pharmaceutical Co.Ltd's market capitalization history from 2015 to 2026. Data shows change from $18.56 Million to $11.34 Million (-4.34% CAGR). Also see ChoA Pharmaceutical Co.Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
ChoA Pharmaceutical Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$235.78 Billion | 0.00% | #1111 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$235.78 Billion | 0.00% | #1111 of 1384 |
Weight: ChoA Pharmaceutical Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ChoA Pharmaceutical Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChoA Pharmaceutical Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ChoA Pharmaceutical Co.Ltd (034940) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
ChoA Pharmaceutical Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $19.44 Million | $55.55 Billion | $163.17 Million | 0.00x | 0.12x |
| 2017 | $19.46 Million | $58.87 Billion | $1.62 Billion | 0.00x | 0.01x |
| 2018 | $18.33 Million | $63.09 Billion | $641.15 Million | 0.00x | 0.03x |
| 2019 | $15.87 Million | $67.54 Billion | -$905.31 Million | 0.00x | N/A |
| 2020 | $20.91 Million | $65.36 Billion | -$1.32 Billion | 0.00x | N/A |
| 2021 | $15.79 Million | $57.56 Billion | -$8.04 Billion | 0.00x | N/A |
| 2022 | $9.89 Million | $68.88 Billion | $560.69 Million | 0.00x | 0.02x |
| 2023 | $8.32 Million | $62.97 Billion | -$10.51 Billion | 0.00x | N/A |
| 2024 | $4.11 Million | $62.69 Billion | -$9.60 Billion | 0.00x | N/A |
| 2025 | $4.24 Million | $59.31 Billion | -$6.81 Billion | 0.00x | N/A |
Competitor Companies of 034940 by Market Capitalization
Companies near ChoA Pharmaceutical Co.Ltd in the global market cap rankings as of September 19, 2026. Review 034940 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ChoA Pharmaceutical Co.Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
ChoA Pharmaceutical Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, ChoA Pharmaceutical Co.Ltd's market cap moved from $18.56 Million to $ 11.34 Million, with a yearly change of -4.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩11.34 Million | +167.33% |
| 2025 | ₩4.24 Million | +3.17% |
| 2024 | ₩4.11 Million | -50.58% |
| 2023 | ₩8.32 Million | -15.88% |
| 2022 | ₩9.89 Million | -37.37% |
| 2021 | ₩15.79 Million | -24.50% |
| 2020 | ₩20.91 Million | +31.75% |
| 2019 | ₩15.87 Million | -13.40% |
| 2018 | ₩18.33 Million | -5.83% |
| 2017 | ₩19.46 Million | +0.11% |
| 2016 | ₩19.44 Million | +4.75% |
| 2015 | ₩18.56 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ChoA Pharmaceutical Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.34 Million USD |
| MoneyControl | $11.34 Million USD |
| MarketWatch | $11.34 Million USD |
| marketcap.company | $11.34 Million USD |
| Reuters | $11.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ChoA Pharmaceutical Co.Ltd
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral ne… Read more